Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 4/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553165 | 1.00 | TRPA1 (0.38) | TRPA1MGLLSMYD3AVPR1AEPHX2 | |
| SCHEMBL25916089 | 0.92 | TRPA1 (0.38) | TRPA1SMYD3EPHX2TACR3 | |
| SCHEMBL30553264 | 0.90 | TRPA1 (0.37) | TRPA1MGLLAVPR1AEPHX2AVPR2 | |
| SCHEMBL25322590 | 0.90 | TRPA1 (0.37) | TRPA1MGLLAVPR1AEPHX2AVPR2 | |
| SCHEMBL25324301 | 0.89 | MGLL (0.36) | MGLLSMYD3AVPR1AAVPR2 | |
| SCHEMBL25324506 | 0.86 | MGLL (0.40) | MGLLEPHX2CCNE1CDK2 | |
| SCHEMBL30553199 | 0.82 | TRPA1 (0.35) | TRPA1MGLLAVPR1A | |
| SCHEMBL25325087 | 0.82 | TRPA1 (0.35) | TRPA1MGLLAVPR1A | |
| SCHEMBL25326703 | 0.81 | MGLL (0.41) | MGLLEPHX2CCNE1CDK2 | |
| SCHEMBL25325125 | 0.81 | MGLL (0.41) | MGLLSMYD3AVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | TRPA1 761/4885MGLL 3523/4885SMYD3 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.